News

AMGN Q2 Deep Dive: Volume Growth, Pipeline Progress, and Guidance Raise Meet Investor Skepticism

Biotech company Amgen (NASDAQ:AMGN) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 9.4% year on year to ...

5 Insightful Analyst Questions From Amgen’s Q2 Earnings Call

Amgen’s second quarter results outpaced Wall Street’s expectations, with management emphasizing strong demand for its ...